Skip to main content

Table 3 Incidence, clearance and prevalence of overall HR-HPV infections at one-year follow-up by age

From: A prospective study of age trends of high-risk human papillomavirus infection in rural China

Age group Crude prevalence, n/N (%) Adjusted prevalence, n/N (%) Adjusted incidence, n/N (%) Clearance, n/N (%) Pa
25-29 15/102 (14.7) 28/302 (9.3) 21/269 (7.8) 26/33 (78.8) 0.560
30-34 35/242 (14.5) 51/598 (8.5) 24/541 (4.4) 30/57 (52.6) 0.497
35-39 91/494 (18.4) 141/1 275 (11.1) 82/1 145 (7.2) 71/130 (54.6) 0.419
40-44 100/593 (16.9) 163/1 503 (10.8) 105/1 339 (7.8) 106/164 (64.6) 1.000
45-49 97/552 (17.6) 125/1 390 (9.0) 57/1 235 (4.6) 87/155 (56.1) 0.015
50-54 91/345 (26.4) 108/877 (12.3) 43/765 (5.6) 47/112 (42.0) 0.752
55-59 100/315 (31.7) 116/801 (14.5) 33/667 (4.9) 51/134 (38.1) 0.063
60-65 46/148 (31.1) 56/363 (15.4) 22/316 (7.0) 13/47 (27.7) 0.175
Total 575/2 791 (20.6) 788/7 109 (11.1) 387/6 277 (6.2) 431/832 (51.8) 0.133
  1. NOTE: Since only a portion of baseline screen negative women were followed up at one-year, incidence was adjusted for the sampling fraction. It was calculated as follows: ((1/sampling fraction) * (Number of baseline screen negatives who tested careHPV-positive at follow-up) + (Number of baseline screen positives with careHPV-negative who tested careHPV-positive at follow-up)) / ((Number of baseline screen negatives) + (Number of baseline screen positives with careHPV-negative who were followed up)). The clearance was simply calculated by: (Number of cleared) / (Number of baseline careHPV-positive who were followed up). The adjusted prevalence at follow up was determined as: ((Number of baseline careHPV-positives who were not cleared) + (Number of incidence)) / Total population. Age groups were defined on the basis of age at baseline. a: the McNemar x2 test is used to test for statistical differences in clearance and incidence; bold type indicates statistical significance (p < 0.05).